A C-Degron Structure-Based Approach for the Development of Ligands Targeting the E3 Ligase TRIM7.

Read more about A C-Degron Structure-Based Approach for the Development of Ligands Targeting the E3 Ligase TRIM7.

Identification of high-performing antibodies for tyrosine-protein kinase SYK for use in Western Blot, immunoprecipitation and immunofluorescence.

Read more about Identification of high-performing antibodies for tyrosine-protein kinase SYK for use in Western Blot, immunoprecipitation and immunofluorescence.

More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication.

Read more about More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication.

A data science roadmap for open science organizations engaged in early-stage drug discovery.

Read more about A data science roadmap for open science organizations engaged in early-stage drug discovery.

Recruitment of FBXO22 for targeted degradation of NSD2.

Read more about Recruitment of FBXO22 for targeted degradation of NSD2.

tracerDB: a crowdsourced fluorescent tracer database for target engagement analysis.

Read more about tracerDB: a crowdsourced fluorescent tracer database for target engagement analysis.

Open Data

Read more about Open Data

A comprehensive strategy sets the stage for a new phase at SGC

Read more about A comprehensive strategy sets the stage for a new phase at SGC

We have brought together the recommendations of a working group composed of experts from the public and private sectors on how to best benefit from recent advances in AI and how to generate, format and disseminate data to enable future breakthroughs in AI-guided drug discovery.

Read more about Huntington's Disease Lab at SGC

03.07.2024

Peter Sampson Joins Agora Open Science Trust as New Vice President of Drug Discovery and Development

by: SGC

Toronto, Ontario – July 3, 2024 – The Structural Genomics Consortium (SGC) is pleased to announce the appointment of Dr. Peter Sampson as the new Vice President of Drug Discovery and Development for SGC’s affiliate Canadian charity, Agora Open Science Trust (Agora).

Subscribe to